Expanded PBS listing for empagliflozin An RACGP expert describes the change as a ‘double win’, with the 1 April expansion to benefit more patients with type 2 diabetes.
Nurse practitioner Jardiance prescribing greenlit It can now be prescribed by NPs as an initial or continuing therapy for chronic heart failure, but the change raises red flags with the RACGP.
Understanding the damage of stigma A lived experience ‘spokesperson’ is on a mission to break down the barriers preventing people from being open with healthcare providers about their drug use.
Drug expanded on PBS for CKD treatment GPs can now prescribe empagliflozin for eligible patients with chronic kidney disease, but should be aware of specific eligibility criteria.
‘Historic’ funding changes for opioid dependency treatment Addiction GPs say the changes will help to reduce barriers when it comes to prescribing and access – and in the process reduce stigma.
GLP-1 RA prescribing checks flagged GPs may soon need Services Australia approval prior to prescribing the diabetes medications, following evidence of ‘high use’ outside of PBS restrictions.
Codeine use down by 37% since up-scheduling Use of the drug has dropped substantially across all jurisdictions, a new wastewater-based epidemiology report suggests.
SGLT2 inhibitors for kidney and heart disease Normally used as a glucose-lowering agent in the treatment of type 2 diabetes, SGLT2 inhibitors have been found to have beneficial effects in patients with heart failure and kidney disease.
Widespread concerns flagged about NPS MedicineWise demise Many worry about the impact on the safe use of medicine, while the transfer of skills is another key issue with employees already leaving.
Clarity on Close the Gap Co-payment initiative Some Aboriginal and Torres Strait Islander patients are being incorrectly told they are no longer able to register for the PBS-subsidised program.